Drug repurposing supported by nanotechnology: a promising strategy to fight cancer

Therapeutic DeliveryVol. 12, No. 4 EditorialDrug repurposing supported by nanotechnology: a promising strategy to fight cancerMohammad NajlahMohammad Najlah *Author for correspondence: E-mail Address: [email protected]://orcid.org/0000-0001-7670-2859Pharmaceutical Research Group, School of Allied Health, Faculty Education, Medicine & Social Care, Anglia Ruskin University, Bishops Hall Lane, Chelmsfordm CM1 1SQ, UKSearch more papers this authorPublished Online:4 Mar 2021https://doi.org/10.4155/tde-2021-0009AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: anticancercopperdisulfiramdrug repurposingliposomesPLGAReferences1. Jemal A, Center MM, Desantis C, Ward EM. Global patterns cancer incidence and mortality rates trends. Cancer Epidemiol. Biomarkers Prev. 19(8), 1893–1907 (2010).Crossref, Medline, Google Scholar2. Bray F, Grey N, Ferlay J, Forman D. transitions according the Human Development Index (2008?2030): population-based study. Lancet Oncol. 13(8), 790–801 (2012).Crossref, Scholar3. Aitken M, Kleinrock Simorellis Nass Oncology Trends 2018, Innovation, Expansion Disruption. 1–61 (2018). www.iqvia.com/insights/the-iqvia-institute/reports/global-oncology-trends-2018Google Scholar4. Yang B, Shi J. Developing new nanomedicines old drugs. Angew. Chem. Int. Ed. Engl. 59(49), 21829–21838 (2020).Crossref, CAS, Scholar5. Said Suliman Tolaymat I et al. injectable PEGylated liposome encapsulating disulfiram colorectal treatment. Pharmaceutics 11(11), 610 (2019).Crossref, Scholar6. Jain Wan KW Ethanol-based proliposome delivery systems paclitaxel in vitro application against brain cells. Liposome Res. 28(1), 74–85 (2018).Crossref, Scholar7. Kadam KW, Ahmed W, Taylor KM, Elhissi AM. Novel formulations solubilized parenteral nutrition nanoemulsions glioma cell lines. Pharm. 506(1–2), 102–109 (2016).Crossref, Scholar8. Teow HM, Zhou Z, Yusof SR, Abbott NJ, D'emanuele A. Delivery across cellular barriers using dendrimer-based nanocarrier. 441(1–2), 701–711 (2013).Crossref, Scholar9. Liu P, Kumar IS, Brown S Disulfiram targets stem-like cells reverses resistance cross-resistance acquired paclitaxel-resistant triple-negative breast Br. 109(7), 1876–1885 Scholar10. Anselmo AC, Mitragotri S. Nanoparticles clinic: an update. Bioeng. Transl. Med. 4(3), e10143 Scholar11. Barenholz Y. Doxil(R)--the first FDA-approved nano-drug: lessons learned. Control Release 160(2), 117–134 Scholar12. Guo X, Xu Pandey Disulfiram/copper complex inhibiting NFkappaB activity potentiating cytotoxic effect gemcitabine on colon Lett. 290(1), 104–113 Scholar13. S, Goktug T Cytotoxic disulfiram/copper human glioblastoma lines ALDH-positive cancer-stem-like 107(9), 1488–1497 Scholar14. Tawari PE, Wang M The mechanisms copper(ii) Toxicol. (Camb). 4(6), 1439–1442 (2015).Crossref, Scholar15. Iqbal characterisation disulfiram-loaded PLGA nanoparticles treatment non-small-cell lung cancer. Eur. Biopharm. 112, 224–233 (2017).Crossref, Scholar16. Tan Mcconville C Poly lactic-co-glycolic acid controlled target liver Nanomedicine 13(2), 641–657 Scholar17. L, Membrane loaded copper oleate combined with improving synergistic antitumor vivo. 35(7), 147 Scholar18. Khoder Cyclodextrin diethyldithiocarbamate II inclusion complexes: chemotherapeutic system chemoresistant triple negative 13(1), 84 (2021).Crossref, ScholarFiguresReferencesRelatedDetailsCited ByPreparation Characterization Beta Inclusion Complexes Potential Application Treatment SARS-CoV-2 via Nebulization31 August 2022 | Molecules, Vol. 27, 17Novel nanoformulation bacterially synthesized oxide augmenting anticancer activity: study6 September 2021 Nanotechnology, 1 Follow us social media latest updates Metrics Downloaded 118 times History Received 23 January Accepted 25 February Published online March print April Information© Newlands PressKeywordsanticancercopperdisulfiramdrug repurposingliposomesPLGAFinancial competing interests disclosureThe author has no relevant affiliations or financial involvement any organization entity interest conflict subject matter materials discussed manuscript. This includes employment, consultancies, honoraria, stock ownership options, expert testimony, grants patents received pending, royalties.No writing assistance was utilized production manuscript.PDF download